Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 8141 results

  1. Our benefits, rewards and work-life balance

    Our staff really enjoy working with us, thanks to our great package of rewards and benefits. We offer flexible ways of working, which means a better

  2. Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)

    Evidence-based recommendations on selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. This involves injecting tiny radioactive spheres into the blood vessels that supply the liver metastases.

  3. NICE International

    An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing

  4. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

  5. Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

    Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

  6. NICE voluntary and community sector forum

    Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...

  7. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

  8. Public board meeting agenda and papers: May 2024

    Agenda and papers of the NICE public board meeting on 15 May 2024

  9. Public board meetings

    Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.

  10. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation

  11. Home testing devices could increase the number of people diagnosed with sleep condition

    Five home-testing devices to diagnose a silent sleep condition seriously harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.

  12. Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer

    More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.

  13. OpenAthens support

    OpenAthens support

  14. Our projects and partners

    NICE research projects and partners.

  15. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer